Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Azelio in connection with a directed share issue of SEK 596 million
Mandate

Vinge has advised Azelio in connection with a directed share issue of SEK 596 million

March 11, 2021 Capital Markets and Public M&A

Vinge has advised Azelio in connection with a directed share issue whereby Azelio raises approximately SEK 596 million in issue proceeds before transaction costs.

The share issue was directed to a number of Swedish and international institutional investors, along with existing shareholders. The main purpose of the share issue is to finance the continued industrialization of Azelio’s Thermal Energy Storage (TES) and Stirling-based electricity production technology with the objective to start series production in the third quarter of 2021, and to be able to finance additional development projects and general corporate purposes. Azelio’s shares are listed on Nasdaq First North Growth Market.

Vinge’s team consisted of David Andersson, William Kåge, Julia Hirschberg and Olof Löfvenberg.

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025